Department of Obstetrics and Gynaecology

Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk (2021) Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindström S, Behrens S, Michailidou K, et al. Journal article NGS zur Selektion innovativer Therapien – Was bringt das? (2021) Schulmeyer C, Bader S, Hübner H, Rübner M, Fasching P Journal article, Review article Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy (2021) Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lübbe K, et al. Journal article An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects (2021) Hajipour H, Farzadi L, Latifi Z, Keyhanvar N, Navali N, Fattahi A, Nouri M, Dittrich R Journal article, Review article Placental thromboinflammation impairs embryonic survival by reducing placental thrombomodulin expression (2021) Kohli S, Singh KK, Gupta A, Markmeyer P, Lochmann F, Gupta D, Rana R, et al. Journal article Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women (2021) Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, Wahlstrom C, Pooley KA, et al. Journal article Is Reduction Mammoplasty Cost-Effective? A Cost-Utility Analysis of Surgical Treatment for Macromastia in Germany (2021) Lux MP, Brendle-Behnisch A, Hack C, Preuss C, Arkudas A, Horch RE, Beckmann M, Jud S Journal article Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane (2021) O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, et al. Conference contribution Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/ trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) Hurvitz SA, Fresco R, Afenjar K, Stroyakovskiy D, Huang CS, Wildiers H, Jung KH, et al. Conference contribution Ribecca - a phase 3b, multi-center, open label study for women with estrogen receptor positive, locally advanced or metastatic breast cancer treated with ribociclib (lee011) in combination with letrozole: Final results (2021) Reinisch M, Nusch A, Decker T, Hartkopf A, Heinrich BJ, Kurbacher CM, Fuchs R, et al. Conference contribution